Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.51 |
| ▸ | MMP3 | P08254 | 3/20 | 0.51 |
| ▸ | MMP7 | P09237 | 3/20 | 0.51 |
| ▸ | MMP12 | P39900 | 3/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 7/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6789133 | 0.82 | MMP3 (0.73) | MMP2MMP3MMP7MMP12ADAM17 | |
| SCHEMBL6790975 | 0.72 | MMP3 (0.72) | MMP2MMP3MMP7MMP12ADAM17 | |
| SCHEMBL7535614 | 0.72 | MMP2 (0.64) | MMP2MMP3MMP7MMP12MMP9 | |
| SCHEMBL6789924 | 0.70 | HDAC1 (0.62) | MMP2MMP3MMP7MMP12ADAM17 | |
| SCHEMBL6219543 | 0.70 | ADAM17 (0.70) | MMP2MMP3MMP7MMP9ADAM17 | |
| SCHEMBL6219552 | 0.70 | ADAM17 (0.70) | MMP2MMP3MMP7MMP9ADAM17 | |
| SCHEMBL6789319 | 0.70 | ADAM17 (0.56) | MMP2MMP3MMP7MMP12ADAM17 | |
| SCHEMBL6790573 | 0.70 | MMP3 (0.72) | MMP2MMP3MMP7MMP12ADAM17 | |
| SCHEMBL6791676 | 0.70 | ADAM17 (0.86) | MMP2MMP3MMP7MMP9ADAM17 | |
| SCHEMBL6790165 | 0.69 | MMP3 (0.73) | MMP2MMP3MMP7MMP12MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6740649-B2 | ANTIINFLAMMATORY AGENTS; OSTEOPOROSIS | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-25 | — | — | US | claimed |
| US-20030139388-A1 | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-07-24 | — | — | US | claimed |
| US-6740649-B2 | ANTIINFLAMMATORY AGENTS; OSTEOPOROSIS | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-25 | — | — | US | disclosed |
| US-20030139388-A1 | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139388-A1 | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAMTS1, MMP1, ADAM17 | MMP2 10/4885MMP3 16/4885MMP7 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.